(NASDAQ: ENLV) Enlivex's forecast annual earnings growth rate of -94.81% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32%.
Enlivex's earnings in 2026 is $3,189,895,000.On average, 3 Wall Street analysts forecast ENLV's earnings for 2026 to be -$19,743,955, with the lowest ENLV earnings forecast at -$18,969,682, and the highest ENLV earnings forecast at -$20,324,659. On average, 3 Wall Street analysts forecast ENLV's earnings for 2027 to be -$3,605,418, with the lowest ENLV earnings forecast at -$3,464,029, and the highest ENLV earnings forecast at -$3,711,460.
In 2028, ENLV is forecast to generate -$1,008,659 in earnings, with the lowest earnings forecast at -$969,103 and the highest earnings forecast at -$1,038,325.